news
创新口服SERD联合依维莫司疗法在晚期ER+ HER2-乳腺癌中显示优越疗效
罗氏宣布giredestrant联合依维莫司的III期研究结果积极，显著降低之前接受过CDK4/6抑制剂治疗的ER+ HER2-晚期乳腺癌患者的疾病进展风险，且具有良好的安全性和生存趋势。
SERD
Latest news
Tag
OB/GYN & Women's Health
Innovative Oral SERD Plus Everolimus Therapy Shows Superior Efficacy in Advanced ER+ HER2- Breast Cancer
Roche announces positive phase 3 results of giredestrant plus everolimus, significantly reducing disease progression risk in ER+ HER2- advanced breast cancer patients post CDK4/6 inhibitor exposure, with favorable safety and promising survi
Clinical Updates
First-Line Camizestrant for ESR1-Mutated Advanced Breast Cancer: Redefining Endocrine Therapy Resistance
Next-generation SERD camizestrant significantly prolongs progression-free survival over aromatase inhibitors or fulvestrant in ESR1-mutated, ER-positive, HER2-negative advanced breast cancer, with favorable safety and quality-of-life profil
